{"entity":{"id":"nct07269782","kind":"trial","name":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","aka":[],"tldr":"A phase 2 trial of Serplulimab in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC is a phase 2 interventional study registered as NCT07269782 by Shanghai Henlius Biotech, with 60 participants planned, started 2026-01-20 and due to reach its primary completion in 2026-07-10. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2, Serplulimab. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07269782","url":"https://clinicaltrials.gov/study/NCT07269782"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["serplulimab"],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07269782","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Combination With Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","sponsor":"Shanghai Henlius Biotech","enrolled":60,"outcomes":[]},"route":"/trials/nct07269782/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}